CCL11 as a potential diagnostic marker for asthma?

Journal of Asthma

Volumn 51, Issue 8, 2014, Pages 847-854

  Wu, Dandan ^a   Zhou, Ji ^a   Bi, Hui ^a   Li, Lingling ^a   Gao, Wei ^a   Huang, Mao ^a   Adcock, Ian M ^b   Barnes, Peter J ^b   Yao, Xin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; Blood; Bronchoalveolar lavage fluid; CCL11; Exhaled breath condensate; Sputum

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; EOTAXIN; INTERLEUKIN 5; NITRIC OXIDE; STEROID; BIOLOGICAL MARKER;

ADULT DISEASE; ANALYTICAL PARAMETERS; ARTICLE; ASTHMA; BREATHING; BRONCHOALVEOLAR LAVAGE FLUID LEVEL; CELL ACTIVATION; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL (TOPIC); CORRELATION COEFFICIENT; DISEASE CONTROL; DISEASE SEVERITY; EMBASE; EOSINOPHIL COUNT; EXHALED BREATH CONDENSATE LEVEL; EXPIRED AIR; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG LAVAGE; MEDLINE; META ANALYSIS; PATHOGENESIS; PREDICTION; PROTEIN BLOOD LEVEL; SPUTUM LEVEL; STEROID THERAPY; SYSTEMATIC REVIEW; BLOOD; BREATH ANALYSIS; CCL11; CHEMISTRY; EXHALED BREATH CONDENSATE; REVIEW; SPUTUM;

ASTHMA; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CCL11; EXHALED BREATH CONDENSATE; SPUTUM;

ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINE CCL11; HUMANS; SPUTUM;

EID: 84907174946     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2014.917659     Document Type: Article

References (65)

1. Krisiukeniene A, Babusyte A, Stravinskaite K, Lotvall J, Sakalauskas R, Sitkauskiene B. Smoking affects eotaxin levels in asthma patients. J Asthma 2009;46:470-476.
2. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Refractory eosinophilic airway inflammation in severe asthma: Effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004;170:601-605.
3. Dent G, Hadjicharalambous C, Yoshikawa T, Handy RL, Powell J, Anderson IK, Louis R, et al. Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am J Respir Crit Care Med 2004;169:1110-1117.
4. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9-16.
5. van Veen IH, Ten Brinke A, Gauw SA, Sterk PJ, Rabe KF, Bel EH. Consistency of sputum eosinophilia in difficult-To-Treat asthma: A 5-year follow-up study. J Allergy Clin Immunol 2009;124: 615-617.
6. Romagnoli M, Vachier I, Tarodo de la Fuente P, Meziane H, Chavis C, Bousquet J, Godard P, Chanez P. Eosinophilic inflammation in sputum of poorly controlled asthmatics. Eur Respir J 2002;20:1370-1377.
7. Wenzel SE. Asthma: Defining of the persistent adult phenotypes. Lancet 2006;368:804-813.
8. Jahnz-Ro yk K, Plusa T, Mierzejewska J. Eotaxin in serum of patients with asthma or chronic obstructive pulmonary disease: Relationship with eosinophil cationic protein and lung function. Mediators Inflamm 2000;9:175-179.
9. Chu YT, Chiang W, Wang TN, Hung CH, Jong YJ, Wu JR. Changes in serum eotaxin and eosinophil cationic protein levels, and eosinophil count during treatment of childhood asthma. J Microbiol Immunol Infect 2007;40:162-167.
10. Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, Allakhverdi Z, Ghaffar O, Rothenberg MD, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997;159:4593-4601.
11. Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27:3507-3516.
12. Hossny E, Ezzat MH, Bakr SI, Soliman M. 48 Elevated plasma and mononuclear cell culture supernate eotaxin levels in asthmatic children. Pediatr Asthma Allergy Immunol 2003;16:137-145.
13. Zhao LL, Lindén A, Sjöstrand M, Cui ZH, Lötvall J, Jordana M. IL-12 regulates bone marrow eosinophilia and airway eotaxin levels induced by airway allergen exposure. Allergy 2000;55:749-756.
14. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Zietkowska E, Bodzenta-Lukaszyk A. Eotaxin in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction. Respiration 2011;82:169-176.
15. Lilly CM, Nakamura H, Belostotsky OI, Haley KJ, Garcia-Zepeda EA, Luster AD, Israel E. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001;163:1669-1675.
16. Eum SY, Maghni K, Hamid Q, Eidelman DH, Campbell H, Isogai S, Martin JG. Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: Role of eosinophils, IL-5, eotaxin, and IL-13. J Allergy Clin Immunol 2003;111:1049-1061.
17. Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, Zietkowska E, Bodzenta-Lukaszyk A. Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients. Respir Res 2010;11:110.
18. Yamamoto K, Takanashi S, Hasegawa Y, Kanehira Y, Kaizuka M, Okumura K. Eotaxin level in induced sputum is increased in patients with bronchial asthma and in smokers. Respiration 2003; 70:600-605.
19. Braunstahl GJ, Fokkens WJ, Overbeek SE, KleinJan A, Hoogsteden HC, Prins JB. Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: A comparison between upper and lower airways. Clin Exp Allergy 2003;33:579-587.
20. Nakamura H, Weiss ST, Israel E, Luster AD, Drazen JM, Lilly CM. Eotaxin and impaired lung function in asthma. Am J Respir Crit Care Med 1999;160:1952-1956.
21. Yamada H, Yamaguchi M, Yamamoto K, Nakajima T, Hirai K, Morita Y, Sano Y, Yamada H. Eotaxin in induced sputum of asthmatics: Relationship with eosinophils and eosinophil cationic protein in sputum. Allergy 2000;55:392-397.
22. Fu J, Chen P, Xiang X. Eotaxin in induced sputum in patients with asthma and chronic bronchitis: Relationship with airway inflammation. Zhonghua Jie He He Hu Xi Za Zhi 2002;25:29-32.
23. Sekiya T, Yamada H, Yamaguchi M, Yamamoto K, Ishii A, Yoshie O, Sano Y, et al. Increased levels of a TH2-Type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 2002;57: 173-177.
24. Park SW, Kim DJ, Chang HS, Park SJ, Lee YM, Park JS, Chung IY, et al. Association of interleukin-5 and eotaxin with acute exacerbation of asthma. Int Arch Allergy Immunol 2003;131:283-290.
25. Jahnz-Rozyk K, Brydak LB, Targowski T, Machala M, Plusa T. Effect of influenza vaccinations on immune response and serum eotaxin level in patients with allergic bronchial asthma. Mediators Inflamm 2004;13:195-199.
26. Liu ZJ, Ren YL, Lin JY, Ni AP. Detection of eotaxin and its clinical diagnosis value in patients with bronchial asthma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004;26:298-301.
27. Tateno H, Nakamura H, Minematsu N, Nakajima T, Takahashi S, Nakamura M, Fukunaga K, et al. Plasma eotaxin level and severity of asthma treated with corticosteroid. Respir Med 2004;98: 782-790.
28. Min JW, Jang AS, Park SM, Lee SH, Lee JH, Park SW, Park CS. Comparison of plasma eotaxin family level in aspirin-induced and aspirin-Tolerant asthma patients. Chest 2005;128:3127-3132.
29. Khor YH, Feltis BN, Reid DW, Ward C, Johns DP, Wood-Baker R, Walters EH. Airway cell and cytokine changes in early asthma deterioration after inhaled corticosteroid reduction. Clin Exp Allergy 2007;37:1189-1198.
30. Wang TN, Chiang W, Tseng HI, Chu YT, Chen WY, Shih NH, Ko YC. The polymorphisms of Eotaxin 1 and CCR3 genes influence on serum IgE, Eotaxin levels and mild asthmatic children in Taiwan. Allergy 2007;62:1125-1130.
31. Xu J, Jiang F, Nayeri F, Zetterstrom O. Apoptotic eosinophils in sputum from asthmatic patients correlate negatively with levels of IL-5 and eotaxin. Respir Med 2007;101:1447-1454.
32. Kim CK, Kita H, Callaway Z, Kim HB, Choi J, Fujisawa T, Shin BM, Koh YY. The roles of a Th2 cytokine and CC chemokine in children with stable asthma: Potential implication in eosinophil degranulation. Pediatr Allergy Immunol 2010;21:e697-704.
33. Korematsu S, Yamamoto K, Nagakura T, Miyahara H, Okazaki N, Akiyoshi K, Maeda T, et al. The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma. Pediatr Allergy Immunol 2010;21:489-492.
34. Muller GC, Pitrez PM, Teixeira AL, Pires PS, Jones MH, Stein RT, Bauer ME. Plasma brain-derived neurotrophic factor levels are associated with clinical severity in school age children with asthma. Clin Exp Allergy 2010;40:1755-1759.
35. Robroeks CM, Rijkers GT, Jobsis Q, Hendriks HJ, Damoiseaux JG, Zimmermann LJ, van Schayck OP, Dompeling E. Increased cytokines, chemokines and soluble adhesion molecules in exhaled breath condensate of asthmatic children. Clin Exp Allergy 2010;40: 77-84.
36. Tillie-Leblond I, Hammad H, Desurmont S, Pugin J, Wallaert B, Tonnel AB, Gosset P, et al. CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus: Potential implication in eosinophil recruitment. Am J Respir Crit Care Med 2000;162:586-592.
37. Tahan F, Karaaslan C, Aslan A, Kiper N, Kalayci O. The role of chemokines in exercise-induced bronchoconstriction in asthma. Ann Allergy Asthma Immunol 2006;96:819-825.
38. Ko FW, Lau CY, Leung TF, Wong GW, Lam CW, Lai CK, Hui DS. Exhaled breath condensate levels of eotaxin and macrophage-derived chemokine in stable adult asthma patients. Clin Exp Allergy 2006;36:44-51.
39. Daldegan MB, Teixeira MM, Talvani A. Concentration of CCL11, CXCL8 and TNF-Alpha in sputum and plasma of patients undergoing asthma or chronic obstructive pulmonary disease exacerbation. Braz J Med Biol Res 2005;38:1359-1365.
40. Snijders D, Agostini S, Bertuola F, Panizzolo C, Baraldo S, Turato G, Faggian D, et al. Markers of eosinophilic and neutrophilic inflammation in bronchoalveolar lavage of asthmatic and atopic children. Allergy 2010;65:978-985.
41. Jahnz-Rozyk K, Plusa T, Mierzejewska J. Blood serum eotaxin and eosinophil cationic protein in asthmatic patients. Pol Merkur Lekarski 2000;8:319-321.
42. Teng Y, Sun P, Zhang J, Yu R, Bai J, Yao X, Huang M, et al. Hydrogen peroxide in exhaled breath condensate in patients with asthma: A promising biomarker?. Chest 2011; 140:108-116.
43. Macedo P, Hew M, Torrego A, Jouneau S, Oates T, Durham A, Chung KF. Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma. Clin Exp Allergy 2009;39:1668-1676.
44. Shannon J, Ernst P, Yamauchi Y, Olivenstein R, Lemiere C, Foley S, Cicora L, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008;133: 420-426.
45. Menzies-Gow A, Robinson DS. Eosinophil chemokines and chemokine receptors: Their role in eosinophil accumulation and activation in asthma and potential as therapeutic targets. J Asthma 2001;38:605-613.
46. Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, Humbert M, Kay AB. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J Immunol 1999;163:6321-6329.
47. Conroy DM, Williams TJ. Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res 2001;2:150-156.
48. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445.
49. Mould AW, Ramsay AJ, Matthaei KI, Young IG, Rothenberg ME, Foster PS. The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity. J Immunol 2000;164:2142-2150.
50. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy. Adv Med Sci 2011;56: 318-322.
51. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 2002;360:1715-1721.
52. Polosa R, Renaud L, Cacciola R, Prosperini G, Crimi N, Djukanovic R. Sputum eosinophilia is more closely associated with airway responsiveness to bradykinin than methacholine in asthma. Eur Respir J 1998;12:551-556.
53. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, Cartier A, et al. Determining asthma treatment by monitoring sputum cell counts: Effect on exacerbations. Eur Respir J 2006;27:483-494.
54. Malerba M, Ragnoli B, Radaeli A, Tantucci C. Usefulness of exhaled nitric oxide and sputum eosinophils in the long-Term control of eosinophilic asthma. Chest 2008;134:733-739.
55. Petsky HL, Kynaston JA, Turner C, Li AM, Cates CJ, Lasserson TJ, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2007;CD005603.
56. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB. A systematic review and meta-Analysis: Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199-208.
57. Lemiere C, Ernst P, Olivenstein R, Yamauchi Y, Govindaraju K, Ludwig MS, Martin JG, Hamid Q. Airway inflammation assessed by invasive and noninvasive means in severe asthma: Eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006;118: 1033-1039.
58. Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, Craig TJ, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005;115:720-727.
59. Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda EA, Rothenberg ME, et al. Expression of eotaxin by human lung epithelial cells: Induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997;99: 1767-1773.
60. Fukakusa M, Bergeron C, Tulic MK, Fiset PO, Al Dewachi O, Laviolette M, Hamid Q, Chakir J. Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa. J Allergy Clin Immunol 2005;115: 280-286.
61. Pang L, Knox AJ. Regulation of TNF-Alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-Agonists and corticosteroids. FASEB J 2001;15:261-269.
62. Papi A, Contoli M, Adcock IM, Bellettato C, Padovani A, Casolari P, Stanciu LA, et al. Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor kappaB and c-Jun N-Terminal kinase activation. J Allergy Clin Immunol 2013;132:1075-1085.
63. Nie M, Knox AJ, Pang L. beta2-Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J Immunol 2005;175:478-486.
64. Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol 2007;157:437-442.
65. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-659.